Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors
C.-W. Chu, T. Caval, F. Alisson-Silva, A. Tankasala, C. Guerrier, G. Czerwieniec, H. Laeubli, F. Schwarz
This study shows that PD-1 glycosylation variants affect the efficacy of immune checkpoint inhibitors and suggests personalized therapeutic approaches.
bioRxiv · Aug 25, 2023Immunology